Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Auro Laboratories Ltd?

Auro Laboratories Ltd is trading at 234.00 as of 13 September 2026, with a FY2026-2027 high of 317 and low of 159. The stock is currently in the middle of its 52-week range. Market cap stands at 146 Cr..

Q: Is Auro Laboratories Ltd financially healthy?

Key indicators: ROCE of 9.52 % is on the lower side. Dividend yield is 0.00 %.

Q: Is Auro Laboratories Ltd profitable and how is the profit trend?

Auro Laboratories Ltd reported a net profit of 2 Cr in Mar 2025 on revenue of 19 Cr. Compared to 3 Cr in Mar 2022, the net profit shows a declining trend.

Fair Value

₹156.69Overvalued by 33.04%vs CMP ₹234.00

P/E (30.4) × ROE (8.5%) × BV (₹74.40) × DY (2.00%)

₹153.54Overvalued by 34.38%vs CMP ₹234.00

MoS: -52.4% (Negative)Confidence: 53/100 (Moderate)Models: 1 Under, 5 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹157.91	33%	Over (-32.5%)
Graham Number	Earnings	₹89.08	24%	Over (-61.9%)
Net Asset Value	Assets	₹74.29	11%	Over (-68.3%)
Earnings Yield	Earnings	₹47.40	11%	Over (-79.7%)
ROCE Capital	Returns	₹480.40	13%	Under (+105.3%)
Revenue Multiple	Revenue	₹31.09	8%	Over (-86.7%)
Consensus (6 models)		₹153.54	100%	Overvalued

Key Drivers: Wide model spread (₹31–₹480) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.8%

*Investments are subject to market risks

Analyst Summary

Auro Laboratories Ltd operates in the Pharmaceuticals segment, NSE: AUROLAB | BSE: 530233, current market price is ₹234.00, market cap is 146 Cr.. At a glance, stock P/E is 30.4, ROE is 8.49 %, ROCE is 9.52 %, book value is 74.4, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹153.54, around 34.4% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹19 Cr versus the prior period change of -63.8%, while latest net profit is about ₹2 Cr with a prior-period change of -76.4%. The 52-week range shown on this page is 317/159, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAuro Laboratories Ltd. is a Public Limited Listed company incorporated on 26/05/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is…

This summary is generated from the stock page data available for Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Auro Laboratories Ltd scores 58/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health58/100 · Moderate

ROCE 9.5% AverageROE 8.5% AverageD/E 0.07 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent

Smart Money50/100 · Moderate

Promoter holding at 52.4% Stable

Earnings Quality75/100 · Strong

OPM expanding (9% → 19%) ImprovingWorking capital: -14 days (improving) Efficient

Quarterly Momentum60/100 · Moderate

Revenue (4Q): +19% YoY GrowingProfit (4Q): -15% YoY DecliningOPM: 43.2% (up 28.5% YoY) Margin expansion

Industry Rank35/100 · Weak

P/E 30.4 vs industry 54.6 Cheaper than peersROCE 9.5% vs industry 25.3% Below peersROE 8.5% vs industry 18.4% Below peers3Y sales CAGR: -27% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 9:27 am

Market Cap	146 Cr.
Current Price	234
Intrinsic Value	₹153.54
High / Low	317/159
Stock P/E	30.4
Book Value	74.4
Dividend Yield	0.00 %
ROCE	9.52 %
ROE	8.49 %
Face Value	10.0
PEG Ratio	39.11

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Auro Laboratories Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Auro Laboratories Ltd	146 Cr.	234	317/159	30.4	74.4	0.00 %	9.52 %	8.49 %	10.0
Bal Pharma Ltd	136 Cr.	85.2	99.0/59.7	18.8	51.6	1.41 %	9.69 %	7.87 %	10.0
Alpa Laboratories Ltd	130 Cr.	61.7	100/46.0	29.7	93.4	0.00 %	8.91 %	7.90 %	10.0
Lactose (India) Ltd	125 Cr.	99.0	137/76.0	18.0	51.5	0.00 %	11.3 %	9.81 %	10.0
Par Drugs & Chemicals Ltd	125 Cr.	101	122/78.0	8.61	91.0	0.00 %	16.5 %	12.4 %	10.0
Industry Average	23,072.45 Cr	1,307.39		54.56	215.82	0.36%	25.34%	18.37%	6.02

All Competitor Stocks of Auro Laboratories Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	15.62	13.52	10.18	13.41	17.98	12.06	5.72	3.10	3.05	7.40	2.77	8.84	9.39
Expenses	15.17	11.17	9.02	10.38	13.90	9.65	4.39	2.38	2.60	6.59	2.74	6.49	5.33
Operating Profit	0.45	2.35	1.16	3.03	4.08	2.41	1.33	0.72	0.45	0.81	0.03	2.35	4.06
OPM %	2.88%	17.38%	11.39%	22.60%	22.69%	19.98%	23.25%	23.23%	14.75%	10.95%	1.08%	26.58%	43.24%
Other Income	0.43	0.62	0.36	0.32	0.42	0.40	0.20	0.31	0.14	0.13	0.42	0.98	0.18
Interest	0.10	0.13	0.27	0.35	0.44	-0.32	0.25	0.28	0.25	0.30	0.28	0.96	1.52
Depreciation	0.27	0.30	0.27	0.27	0.27	0.28	0.27	0.27	0.27	0.29	0.27	0.65	0.98
Profit before tax	0.51	2.54	0.98	2.73	3.79	2.85	1.01	0.48	0.07	0.35	-0.10	1.72	1.74
Tax %	27.45%	29.53%	27.55%	27.84%	27.70%	18.60%	24.75%	25.00%	28.57%	-11.43%	0.00%	58.14%	-12.07%
Net Profit	0.37	1.78	0.71	1.97	2.73	2.32	0.75	0.36	0.05	0.39	-0.11	0.72	1.95
EPS in Rs	0.59	2.86	1.14	3.16	4.38	3.72	1.20	0.58	0.08	0.63	-0.18	1.16	3.13

Last Updated: March 3, 2026, 12:04 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:30 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	33.74	32.65	27.91	35.47	40.79	46.82	43.79	54.25	50.87	52.89	53.64	19.40	28.40
Expenses	30.95	29.71	25.11	31.03	34.43	39.83	37.51	43.01	46.24	48.50	42.96	16.00	21.15
Operating Profit	2.79	2.94	2.80	4.44	6.36	6.99	6.28	11.24	4.63	4.39	10.68	3.40	7.25
OPM %	8.27%	9.00%	10.03%	12.52%	15.59%	14.93%	14.34%	20.72%	9.10%	8.30%	19.91%	17.53%	25.53%
Other Income	0.06	0.24	0.42	0.53	0.51	0.96	0.97	0.76	1.09	0.94	1.50	0.66	1.71
Interest	1.53	1.66	1.66	1.18	1.21	0.87	0.58	0.46	0.83	0.81	0.74	1.08	3.06
Depreciation	0.74	0.72	0.68	0.86	0.93	1.01	1.02	1.04	1.02	1.07	1.09	1.10	2.19
Profit before tax	0.58	0.80	0.88	2.93	4.73	6.07	5.65	10.50	3.87	3.45	10.35	1.88	3.71
Tax %	0.00%	0.00%	0.00%	72.01%	25.16%	27.51%	27.96%	31.62%	26.61%	28.99%	24.64%	2.13%
Net Profit	0.58	0.80	0.88	0.82	3.53	4.40	4.05	7.18	2.84	2.44	7.79	1.84	2.95
EPS in Rs	0.93	1.28	1.41	1.32	5.66	7.06	6.50	11.52	4.56	3.91	12.50	2.95	4.74
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	37.93%	10.00%	-6.82%	330.49%	24.65%	-7.95%	77.28%	-60.45%	-14.08%	219.26%	-76.38%
Change in YoY Net Profit Growth (%)	0.00%	-27.93%	-16.82%	337.31%	-305.84%	-32.60%	85.24%	-137.73%	46.36%	233.35%	-295.64%

Auro Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	-5%
5 Years:	-15%
3 Years:	-27%
TTM:	-67%

Compounded Profit Growth
10 Years:	9%
5 Years:	-15%
3 Years:	-13%
TTM:	-91%

Stock Price CAGR
10 Years:	34%
5 Years:	33%
3 Years:	42%
1 Year:	23%

Return on Equity
10 Years:	15%
5 Years:	13%
3 Years:	11%
Last Year:	4%

Last Updated: September 5, 2025, 2:31 pm

Balance Sheet

Last Updated: August 5, 2026, 1:30 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23
Reserves	1.47	2.35	3.18	6.75	11.18	15.27	22.35	25.29	27.97	35.73	36.74	40.12
Borrowings	16.41	12.62	4.95	9.20	8.09	3.16	3.16	13.78	6.41	26.25	45.01	63.31
Other Liabilities	4.67	4.49	12.45	8.23	7.97	7.68	10.15	9.66	15.38	17.52	11.11	11.42
Total Liabilities	28.78	25.69	26.81	30.41	33.47	32.34	41.89	54.96	55.99	85.73	99.09	121.08
Fixed Assets	9.80	9.13	13.00	13.02	14.59	14.24	13.56	13.61	12.62	22.15	21.06	75.18
CWIP	0.82	3.33	0.23	1.07	0.12	0.12	0.13	3.68	7.67	32.68	56.48	14.48
Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.01
Other Assets	18.11	13.18	13.53	16.27	18.71	17.93	28.15	37.62	35.65	30.85	21.50	31.41
Total Assets	28.78	25.69	26.81	30.41	33.47	32.34	41.89	54.96	55.99	85.73	99.09	121.08

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	-0.78	7.88	6.49	6.05	6.87	9.30	12.82	-6.59	3.28	18.81	5.02	2.11
Cash from Investing Activity +	-0.73	-2.44	-2.20	-3.04	-3.19	-2.21	-3.51	-5.34	-5.08	-38.67	-23.70	-14.78
Cash from Financing Activity +	0.53	-5.34	-3.81	-1.77	-1.83	-5.52	-0.46	9.79	-8.18	19.09	17.69	14.04
Net Cash Flow	-0.98	0.09	0.47	1.24	1.86	1.58	8.85	-2.14	-9.98	-0.77	-0.99	1.37
Free Cash Flow	-1.55	5.36	4.86	4.25	5.25	8.63	12.44	-11.20	-0.79	18.81	-18.78	-55.03
CFO/OP	-27%	281%	146%	95%	98%	148%	114%	-142%	75%	176%	184%	21%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	2.79	-13.47	-9.82	-0.51	-2.84	-1.10	3.12	8.08	-9.15	-2.02	-15.57	-41.61

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	46.95	94.80	66.04	79.13	74.90	66.26	48.18	49.12	97.65	85.57	91.11	176.67
Inventory Days	115.33	89.37	86.72	21.65	22.00	42.98	60.54	32.60	47.32	120.27	113.24	145.45
Days Payable	62.97	56.12	72.03	80.26	78.26	66.19	70.67	73.51	54.12	117.41	85.34	246.11
Cash Conversion Cycle	99.30	128.05	80.73	20.52	18.64	43.05	38.04	8.20	90.86	88.44	119.01	76.01
Working Capital Days	19.15	39.13	26.68	67.20	64.70	63.46	51.09	29.40	36.59	104.28	35.86	-14.30
ROCE %	9.43%	10.74%	11.21%	23.06%	32.51%	29.11%	24.84%	38.87%	12.20%	9.92%	20.38%	3.85%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	52.09%	52.09%	52.15%	52.15%	52.15%	52.15%	52.17%	52.17%	52.17%	52.17%	52.17%	52.40%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	47.92%	47.90%	47.85%	47.84%	47.84%	47.84%	47.82%	47.82%	47.82%	47.80%	47.82%	47.58%
No. of Shareholders	10,272	9,905	9,441	9,335	9,266	9,265	9,102	8,916	8,860	8,640	8,405	8,315

Shareholding Pattern Chart

No. of Shareholders

Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	2.95	12.50	3.92	4.56	11.52
Diluted EPS (Rs.)	2.95	12.50	3.92	4.56	11.52
Cash EPS (Rs.)	4.71	14.26	5.64	6.20	13.18
Book Value[Excl.RevalReserv]/Share (Rs.)	68.94	67.32	54.87	50.58	45.86
Book Value[Incl.RevalReserv]/Share (Rs.)	68.94	67.32	54.87	50.58	45.86
Revenue From Operations / Share (Rs.)	31.12	86.06	84.87	81.61	87.05
PBDIT / Share (Rs.)	6.51	19.53	8.56	9.17	19.25
PBIT / Share (Rs.)	4.75	17.78	6.83	7.54	17.59
PBT / Share (Rs.)	3.02	16.60	5.53	6.21	16.86
Net Profit / Share (Rs.)	2.95	12.50	3.92	4.56	11.52
PBDIT Margin (%)	20.92	22.69	10.08	11.24	22.11
PBIT Margin (%)	15.27	20.66	8.05	9.24	20.20
PBT Margin (%)	9.69	19.28	6.51	7.61	19.36
Net Profit Margin (%)	9.47	14.52	4.61	5.59	13.23
Return on Networth / Equity (%)	4.27	18.57	7.14	9.02	25.11
Return on Capital Employeed (%)	3.82	17.93	11.25	13.49	32.80
Return On Assets (%)	1.85	9.08	4.36	5.17	17.13
Long Term Debt / Equity (X)	0.71	0.43	0.05	0.02	0.07
Total Debt / Equity (X)	0.99	0.62	0.18	0.02	0.07
Asset Turnover Ratio (%)	0.20	0.75	0.95	1.05	1.46
Current Ratio (X)	0.99	1.29	1.97	1.87	3.32
Quick Ratio (X)	0.82	0.94	1.32	1.66	3.02
Inventory Turnover Ratio (X)	3.26	2.90	4.66	9.92	8.30
Interest Coverage Ratio (X)	3.75	16.55	6.55	6.92	26.18
Interest Coverage Ratio (Post Tax) (X)	2.70	11.59	4.00	4.44	16.66
Enterprise Value (Cr.)	185.78	125.03	37.80	50.97	38.05
EV / Net Operating Revenue (X)	9.58	2.33	0.71	1.00	0.70
EV / EBITDA (X)	45.76	10.27	7.09	8.91	3.17
MarketCap / Net Operating Revenue (X)	7.41	1.87	0.64	1.23	0.93
Price / BV (X)	3.34	2.39	0.99	1.98	1.77
Price / Net Operating Revenue (X)	7.41	1.87	0.64	1.23	0.93
EarningsYield	0.01	0.07	0.07	0.04	0.14

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Auro Laboratories Ltd and is it undervalued?

As of 13 September 2026, Auro Laboratories Ltd's intrinsic value is ₹153.54, which is 34.38% lower than the current market price of ₹234.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (8.49 %), book value (₹74.4), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Auro Laboratories Ltd?

Auro Laboratories Ltd is trading at ₹234.00 as of 13 September 2026, with a FY2026-2027 high of ₹317 and low of ₹159. The stock is currently in the middle of its 52-week range. Market cap stands at ₹146 Cr..

How does Auro Laboratories Ltd's P/E ratio compare to its industry?

Auro Laboratories Ltd has a P/E ratio of 30.4, which is below the industry average of 54.56. This is broadly in line with or below the industry average.

Is Auro Laboratories Ltd financially healthy?

Key indicators for Auro Laboratories Ltd: ROCE of 9.52 % is on the lower side compared to the industry average of 25.34%. Dividend yield is 0.00 %.

Is Auro Laboratories Ltd profitable and how is the profit trend?

Auro Laboratories Ltd reported a net profit of ₹2 Cr in Mar 2025 on revenue of ₹19 Cr. Compared to ₹3 Cr in Mar 2022, the net profit shows a declining trend.

Does Auro Laboratories Ltd pay dividends?

Auro Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹234.00. The company is currently not paying meaningful dividends.